DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis

Abstract

Simple models of therapy for viral diseases such as hepatitis C virus (HCV) or human immunodeficiency virus assume that, once therapy is started, the drug has a constant effectiveness. More realistic models have assumed either that the drug effectiveness depends on the drug concentration or that the effectiveness varies over time. Here a previously introduced varying-effectiveness (VE) model is studied mathematically in the context of HCV infection. We show that while the model is linear, it has no closed-form solution due to the time-varying nature of the effectiveness. We then show that the model can be transformed into a Bessel equation and derive an analytic solution in terms of modified Bessel functions, which are defined as infinite series, with time-varying arguments. Fitting the solution to data from HCV infected patients under therapy has yielded values for the parameters in the model. We show that for biologically realistic parameters, the predicted viral decay on therapy is generally biphasic and resembles that predicted by constant-effectiveness (CE) models. We introduce a general method for determining the time at which the transition between decay phases occurs based on calculating the point of maximum curvature of the viral decay curve. For the parameter regimes ofmore » interest, we also find approximate solutions for the VE model and establish the asymptotic behavior of the system. We show that the rate of second phase decay is determined by the death rate of infected cells multiplied by the maximum effectiveness of therapy, whereas the rate of first phase decline depends on multiple parameters including the rate of increase of drug effectiveness with time.« less

Authors:
 [1];  [1]
  1. Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
Publication Date:
Research Org.:
Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
Sponsoring Org.:
USDOE Office of Science (SC), Biological and Environmental Research (BER). Biological Systems Science Division; National Institutes of Health (NIH)
OSTI Identifier:
1627237
Grant/Contract Number:  
AC52-06NA25396; R01-OD011095; R01-AI078881; R34-HL109334; P20-GM103452; R01-AI028433
Resource Type:
Accepted Manuscript
Journal Name:
PLoS Computational Biology (Online)
Additional Journal Information:
Journal Name: PLoS Computational Biology (Online); Journal Volume: 10; Journal Issue: 8; Journal ID: ISSN 1553-7358
Publisher:
Public Library of Science
Country of Publication:
United States
Language:
English
Subject:
59 BASIC BIOLOGICAL SCIENCES; Biochemistry & Molecular Biology; Mathematical & Computational Biology

Citation Formats

Conway, Jessica M., and Perelson, Alan S. A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis. United States: N. p., 2014. Web. doi:10.1371/journal.pcbi.1003769.
Conway, Jessica M., & Perelson, Alan S. A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis. United States. https://doi.org/10.1371/journal.pcbi.1003769
Conway, Jessica M., and Perelson, Alan S. Thu . "A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis". United States. https://doi.org/10.1371/journal.pcbi.1003769. https://www.osti.gov/servlets/purl/1627237.
@article{osti_1627237,
title = {A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis},
author = {Conway, Jessica M. and Perelson, Alan S.},
abstractNote = {Simple models of therapy for viral diseases such as hepatitis C virus (HCV) or human immunodeficiency virus assume that, once therapy is started, the drug has a constant effectiveness. More realistic models have assumed either that the drug effectiveness depends on the drug concentration or that the effectiveness varies over time. Here a previously introduced varying-effectiveness (VE) model is studied mathematically in the context of HCV infection. We show that while the model is linear, it has no closed-form solution due to the time-varying nature of the effectiveness. We then show that the model can be transformed into a Bessel equation and derive an analytic solution in terms of modified Bessel functions, which are defined as infinite series, with time-varying arguments. Fitting the solution to data from HCV infected patients under therapy has yielded values for the parameters in the model. We show that for biologically realistic parameters, the predicted viral decay on therapy is generally biphasic and resembles that predicted by constant-effectiveness (CE) models. We introduce a general method for determining the time at which the transition between decay phases occurs based on calculating the point of maximum curvature of the viral decay curve. For the parameter regimes of interest, we also find approximate solutions for the VE model and establish the asymptotic behavior of the system. We show that the rate of second phase decay is determined by the death rate of infected cells multiplied by the maximum effectiveness of therapy, whereas the rate of first phase decline depends on multiple parameters including the rate of increase of drug effectiveness with time.},
doi = {10.1371/journal.pcbi.1003769},
journal = {PLoS Computational Biology (Online)},
number = 8,
volume = 10,
place = {United States},
year = {Thu Aug 07 00:00:00 EDT 2014},
month = {Thu Aug 07 00:00:00 EDT 2014}
}

Works referenced in this record:

Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?
journal, May 2014


Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy
journal, June 1999

  • Tsiang, Manuel; Rooney, James F.; Toole, John J.
  • Hepatology, Vol. 29, Issue 6
  • DOI: 10.1002/hep.510290626

On the exponential solution of differential equations for a linear operator
journal, November 1954


Modeling amantadine treatment of influenza A virus in vitro
journal, September 2008

  • Beauchemin, Catherine A. A.; McSharry, James J.; Drusano, George L.
  • Journal of Theoretical Biology, Vol. 254, Issue 2
  • DOI: 10.1016/j.jtbi.2008.05.031

Modelling viral and immune system dynamics
journal, January 2002

  • Perelson, Alan S.
  • Nature Reviews Immunology, Vol. 2, Issue 1
  • DOI: 10.1038/nri700

Silibinin mode(s) of action against hepatitis C virus: A controversy yet to be resolved
journal, June 2011

  • Dahari, Harel; Guedj, Jeremie; Perelson, Alan S.
  • Hepatology, Vol. 54, Issue 2
  • DOI: 10.1002/hep.24310

Modelling the kinetics of hepatitis C virus RNA decline over 4 weeks of treatment with pegylated interferon α-2b
journal, May 2008


A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure
journal, May 2010

  • Snoeck, E.; Chanu, P.; Lavielle, M.
  • Clinical Pharmacology & Therapeutics, Vol. 87, Issue 6
  • DOI: 10.1038/clpt.2010.35

Modeling HCV kinetics under therapy using PK and PD information
journal, March 2009

  • Shudo, Emi; Ribeiro, Ruy M.; Perelson, Alan S.
  • Expert Opinion on Drug Metabolism & Toxicology, Vol. 5, Issue 3
  • DOI: 10.1517/17425250902787616

Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon- Therapy
journal, October 1998


Modelling how ribavirin improves interferon response rates in hepatitis C virus infection
journal, December 2004

  • Dixit, Narendra M.; Layden-Almer, Jennifer E.; Layden, Thomas J.
  • Nature, Vol. 432, Issue 7019
  • DOI: 10.1038/nature03153

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
journal, February 2013

  • Guedj, J.; Dahari, H.; Rong, L.
  • Proceedings of the National Academy of Sciences, Vol. 110, Issue 10
  • DOI: 10.1073/pnas.1203110110

Mathematical Analysis of HIV-1 Dynamics in Vivo
journal, January 1999


Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model
journal, March 2013


Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus
journal, May 2010


Modelling hepatitis C virus kinetics during treatment with pegylated interferon α-2b: errors in the estimation of viral kinetic parameters
journal, May 2008


The Magnus expansion and some of its applications
journal, January 2009


Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay
journal, January 2004


Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy
journal, January 2014

  • Canini, Laetitia; DebRoy, Swati; Mariño, Zoe
  • Antiviral Therapy, Vol. 20, Issue 2
  • DOI: 10.3851/IMP2806

Kinetics of Influenza A Virus Infection in Humans
journal, July 2006

  • Baccam, P.; Beauchemin, C.; Macken, C. A.
  • Journal of Virology, Vol. 80, Issue 15
  • DOI: 10.1128/JVI.01623-05

Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)
journal, February 2012

  • Guedj, Jeremie; Dahari, Harel; Shudo, Emi
  • Hepatology, Vol. 55, Issue 4
  • DOI: 10.1002/hep.24788

Pharmacodynamics of PEG-IFN α differentiate HIV/HCV coinfected sustained virological responders from nonresponders
journal, May 2006

  • Talal, Andrew H.; Ribeiro, Ruy M.; Powers, Kimberly A.
  • Hepatology, Vol. 43, Issue 5
  • DOI: 10.1002/hep.21136

Understanding silibinin’s modes of action against HCV using viral kinetic modeling
journal, May 2012


Modeling complex decay profiles of hepatitis B virus during antiviral therapy
journal, August 2008

  • Dahari, Harel; Shudo, Emi; Ribeiro, Ruy M.
  • Hepatology, Vol. 49, Issue 1
  • DOI: 10.1002/hep.22586

Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs)
journal, September 2004


Pharmacodynamics of PEG-IFN-α-2a in HIV/HCV co-infected patients: Implications for treatment outcomes
journal, September 2010

  • Dahari, Harel; Affonso de Araujo, Evaldo S.; Haagmans, Bart L.
  • Journal of Hepatology, Vol. 53, Issue 3
  • DOI: 10.1016/j.jhep.2010.03.019

Pharmacodynamics of PEG-IFN α differentiate HIV/HCV coinfected sustained virological responders from nonresponders
journal, May 2006

  • Talal, Andrew H.; Ribeiro, Ruy M.; Powers, Kimberly A.
  • Hepatology, Vol. 43, Issue 5
  • DOI: 10.1002/hep.21136

Modeling complex decay profiles of hepatitis B virus during antiviral therapy
journal, August 2008

  • Dahari, Harel; Shudo, Emi; Ribeiro, Ruy M.
  • Hepatology, Vol. 49, Issue 1
  • DOI: 10.1002/hep.22586

Multiple effects of silymarin on the hepatitis C virus lifecycle
journal, February 2010

  • Wagoner, Jessica; Negash, Amina; Kane, Olivia J.
  • Hepatology, Vol. 51, Issue 6
  • DOI: 10.1002/hep.23587

Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)
journal, February 2012

  • Guedj, Jeremie; Dahari, Harel; Shudo, Emi
  • Hepatology, Vol. 55, Issue 4
  • DOI: 10.1002/hep.24788

Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?
journal, May 2014


Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs)
journal, September 2004


Mathematical modeling: A tool for selecting agents with complementary modes of action?
journal, December 2013


Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay
journal, January 2004


Modelling how ribavirin improves interferon response rates in hepatitis C virus infection
journal, December 2004

  • Dixit, Narendra M.; Layden-Almer, Jennifer E.; Layden, Thomas J.
  • Nature, Vol. 432, Issue 7019
  • DOI: 10.1038/nature03153

Modelling viral and immune system dynamics
journal, January 2002

  • Perelson, Alan S.
  • Nature Reviews Immunology, Vol. 2, Issue 1
  • DOI: 10.1038/nri700

Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon- Therapy
journal, October 1998


Analysis of the hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938
journal, January 2014

  • Guedj, Jeremie; Pang, Phillip S.; Denning, Jill
  • Antiviral Therapy, Vol. 19, Issue 2
  • DOI: 10.3851/imp2733